sarepta - Search News

Sarepta Shares Fall on Report of Patient Death

Associated Press News on MSN · 1d

Patient dies following muscular dystrophy gene therapy, Sarepta reports

A patient has died while taking a closely watched gene therapy for muscular dystrophy. Sarepta Therapeutics announced the death Tuesday morning, sending the company's shares plummeting in morning trading.

The Wall Street Journal · 1d

Gene-Therapy Maker Sarepta Tanks After Patient Death

Shares of Sarepta Therapeutics have struggled for the past year due to concerns about the commercial potential of its gene therapy and broader pipeline. Safety hadn’t been a major worry for investors—

U.S. News & World Report · 15h

Sarepta’s Gene Therapy Under Scrutiny After Patient Death

The company behind the drug, Sarepta Therapeutics, said that the patient suffered acute liver injury, a known side effect, The Associated Press reported. However, the "severity" of this case had not been seen before, the company noted. Elevidys has been used in more than 800 patients, the company stated.

Sarepta Therapeutics stock falls

Investopedia on MSN · 1d

Sarepta Therapeutics Stock Sinks After Company Says Patient Taking Its Drug Dies

Sarepta Therapeutics said a patient taking its treatment for Duchenne muscular dystrophy has died from acute liver failure. The pharmaceutical firm said that "acute liver injury is a known possible side effect of Elevidys.

MarketWatch on MSN · 1d

Sarepta Therapeutics’ stock falls after patient dies of liver failure

The company said that more than 800 people have been treated with Elevidys, with only one experiencing liver failure.

Markets Insider · 15h

Patient Fatality Forces Reality Check on Sarepta Therapeutics Stock (SRPT)

Sarepta Therapeutics (SRPT) stock is reeling this week following the death of a 16-year-old patient treated with its flagship gene therapy,

4hon MSN

Why Sarepta Therapeutics Inc. (SRPT) Went Up On Wednesday?

Wednesday’s 10 Top Performers. In this article, we are going to take a look at where Sarepta Therapeutics Inc. (NASDAQ:SRPT) ...

16hon MSN

Why Sarepta Therapeutics Inc. (SRPT) Crashed On Tuesday?

We recently published a list of 10 Firms Heavily Hit by Market Pessimism. In this article, we are going to take a look at ...

1d

Teenager who received Elevidys, Sarepta’s Duchenne gene therapy, dies

Elevidys was approved after intense debate at the FDA, as officials and reviewers disagreed over how strong the evidence was ...

1d

Ticker: Sarepta reports death in drug trial; Google makes $32B cybersecurity deal

Cambridge-based Sarepta Therapeutics said Tuesday that a patient died while taking its closely watched gene therapy for ...

17h

Sarepta weakness ‘compelling’ buying opportunity, says Mizuho

Mizuho views the selloff in shares of Sarepta (SRPT) yesterday due to concerns about Elevidys adoption as a result of the fatal acute liver ...

MPR12h

Patient Dies Following Treatment With DMD Gene Therapy Elevidys

The Company is currently analyzing the case and will update the prescribing information for Elevidys to note this development.

BioPharma Dive1d

Duchenne patient dies after receiving Sarepta gene therapy

A young man treated with Elevidys died of acute liver failure. The case may give doctors pause before prescribing the ...

21h

Sarepta Therapeutics (NASDAQ:SRPT) Earns Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results